Clinical Practice Guidelines for Cancer Screening in Patients with Autoimmune Diseases: A Systematic Review

Vikas Burugu1; Juan I. Ruiz, MD, MPH2; Maria A. López-Olivo, MD, PhD2; Maria E. Suarez-Almazor, MD, PhD2

1University of Texas at Austin, Austin, TX, USA; 2Health Services Research, The University of Texas, MD Anderson Cancer Center, Houston, USA

Background

- Autoimmune disorders are generally characterized by the immune system attacking healthy tissue.

- Autoimmune diseases have been linked with a higher risk of malignancies. The chronic inflammation prompted by autoimmune conditions can dysregulate the immune system and stimulate cancer growth.

- New biological anti-rheumatic drugs for the treatment of rheumatoid arthritis and other inflammatory rheumatoid diseases could potentially be associated with a higher risk of malignancies compared to old treatments.

- Autoimmune conditions are treated with immunosuppressive therapies, which undermine the immune system’s ability to target cancer cells.

- Cancers that have recommendations for screening in the general population include colon, cervical, breast, lung, and skin cancer.

- Although patients with autoimmune diseases are at a higher risk of cancer compared to the general population, recommendations for these patients are sparse.

Objective

To identify and evaluate the recommendation statements regarding cancer screening for patients with a history of rheumatoid arthritis, ankylosing spondylarthritis, or systemic lupus erythematosus.

Methods

Information Sources

We identified potential CPGs and consensus statements by searching six electronic databases (Medline, EMBASE, Web of Science, Scopus, CINAHL, PubMed, and Cochrane Library) from 2018 afterward. NICE UK, TRIP Database, DynaMed, and a list of rheumatological societies (areas of grey literature) were hand-searched.

Eligibility Criteria

We included CPGs and consensus statements in English for cancer screening in patients with rheumatic conditions. Primary studies (including clinical trials, observational studies, and cross-sectional studies) were excluded. The autoimmune diseases of interest were rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and ankylosing spondylarthritis (SpA). Cancers that were considered were cervical, colorectal, breast, lung, and skin cancer.

Procedure

Two reviewers independently evaluated eligibility using the title and abstract of the CPGs and consensus statements. In the case of a conflict, reasons for exclusion were discussed by both reviewers. If there was no consensus, a third reviewer was consulted. Using the CPGs and consensus statements that were included in this first screening step, the same reviewers reviewed the full text. CPGs and consensus statements about cancer screening or guidelines about rheumatoid arthritis, systemic lupus erythematosus, and spondylarthritis were included. We are currently in the process of data extraction.

Outcomes

We will evaluate whether a recommendation is present, what type of screening the recommendation suggests, the frequency of screening, and quality and nature of evidence to support recommendations.

Future Direction

- We will analyze the recommendations and statements for cancer screening in patients with RA, SLE, or SpA. Using the AGREE-Rex tool, we will appraise the quality of guidelines.

- We will assess the general characteristics of the selected studies (country of origin, target audience, funding source, and topic) and elucidate patterns/trends in CPGs and consensus statements.

References


The research described was supported in part by a cancer prevention fellowship for Vikas Burugu supported by the National Cancer Institute grant R25E (CA056452, Shine Chang, Ph.D., Principal Investigator).